NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free AVDL Stock Alerts $16.52 +0.69 (+4.36%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$15.70▼$17.1450-Day Range$13.72▼$18.8252-Week Range$9.50▼$19.09Volume1.89 million shsAverage Volume1.34 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$24.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Avadel Pharmaceuticals alerts: Email Address Avadel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.3% Upside$24.17 Price TargetShort InterestHealthy5.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 31 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.74 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector265th out of 921 stocksPharmaceutical Preparations Industry111th out of 428 stocks 4.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avadel Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.30% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 54.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.4 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Avadel Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows9 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 18.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More AVDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Stock News HeadlinesMay 11, 2024 | americanbankingnews.comAvadel Pharmaceuticals plc to Post Q4 2024 Earnings of $0.00 Per Share, Lifesci Capital Forecasts (NASDAQ:AVDL)May 11, 2024 | americanbankingnews.comAnalysts Offer Predictions for Avadel Pharmaceuticals plc's Q4 2024 Earnings (NASDAQ:AVDL)May 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 11, 2024 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Up 5.2% After Analyst UpgradeMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market ExpansionMay 10, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Avadel Pharmaceuticals (NASDAQ:AVDL)May 10, 2024 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Stock Price Down 7.3% on Disappointing EarningsMay 9, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call TranscriptMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 8, 2024 | msn.comAvadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28MMay 8, 2024 | investorplace.comAVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...May 8, 2024 | globenewswire.comAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8April 29, 2024 | finance.yahoo.comWall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should KnowApril 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday TradingApril 21, 2024 | money.usnews.comAvadel Pharmaceuticals plcApril 16, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (AVDL)April 11, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near FutureApril 2, 2024 | seekingalpha.comAvadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly RevolutionApril 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comAVDL Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 10.000 putMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth ProspectsMarch 5, 2024 | seekingalpha.comAvadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation OverhangSee More Headlines Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/11/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees154Year Founded2015Price Target and Rating Average Stock Price Target$24.17 High Stock Price Target$29.00 Low Stock Price Target$21.00 Potential Upside/Downside+46.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-284.42% Pretax Margin-284.11% Return on Equity-139.72% Return on Assets-79.53% Debt Debt-to-Equity RatioN/A Current Ratio2.85 Quick Ratio3.36 Sales & Book Value Annual Sales$27.96 million Price / Sales53.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book18.99Miscellaneous Outstanding Shares90,580,000Free Float86,954,000Market Cap$1.50 billion OptionableOptionable Beta1.61 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gregory J. Divis Jr. (Age 57)CEO & Director Comp: $985.2kMr. Thomas S. McHugh (Age 59)Senior VP, Principal Financial and Accounting Officer & CFO Comp: $663.14kMr. Richard J. Kim (Age 55)Chief Commercial Officer Comp: $770.95kMr. Jerad G. SeurerGeneral Counsel & Company SecretaryMr. Gregory J. Davis (Age 59)VP of Corporate and Business Development Mr. Mark W. ElrodVice President of SalesMs. Angie WoodsVice President of People & CultureDr. Jordan S. Dubow M.D. (Age 45)Consultant Comp: $727.93kDr. Jason M. VaughnSenior Vice President of Technical OperationsMs. Jennifer Gudeman PharmDSenior Vice President of Medical & Clinical AffairsMore ExecutivesKey CompetitorsZai LabNASDAQ:ZLABKura OncologyNASDAQ:KURATaro Pharmaceutical IndustriesNYSE:TAROSupernus PharmaceuticalsNASDAQ:SUPNSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsLord Abbett & CO. LLCBought 193,233 shares on 5/9/2024Ownership: 0.213%Russell Investments Group Ltd.Bought 115,041 shares on 5/8/2024Ownership: 0.127%Avantax Advisory Services Inc.Bought 30,856 shares on 5/8/2024Ownership: 0.062%Oppenheimer & Co. Inc.Sold 816 shares on 5/7/2024Ownership: 0.041%Chilton Capital Management LLCBought 3,000 shares on 5/7/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions AVDL Stock Analysis - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price target for 2024? 6 equities research analysts have issued 12 month price objectives for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $21.00 to $29.00. On average, they expect the company's share price to reach $24.17 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2024? Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of the year. Since then, AVDL stock has increased by 17.0% and is now trading at $16.52. View the best growth stocks for 2024 here. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Wednesday, May, 8th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.05. The business earned $27.18 million during the quarter, compared to analyst estimates of $25.89 million. Avadel Pharmaceuticals had a negative net margin of 284.42% and a negative trailing twelve-month return on equity of 139.72%. The firm's revenue was up 2617.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.48) EPS. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (4.39%), Wealth Effects LLC (2.50%), Obermeyer Wood Investment Counsel Lllp (0.31%), Lord Abbett & CO. LLC (0.21%), Schulhoff & Co. Inc. (0.15%) and Russell Investments Group Ltd. (0.13%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVDL) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial Metals[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.